F8 and hemophilia A: Following exclusion criteria, 1535 people with severe hemophilia A without an inhibitor were included in the study, of whom 618 (40.3%) switched to emicizumab prophylaxis and 917 (59.7%) continued treatment with prophylactic or on-demand FVIII (Figure 1, Table 1).